Clinical information about thiotepa-based autologous stem cell transplantation (auto-SCT) outside the primary central nervous system lymphoma (PCNSL) field is sparse. In this registry-based retrospective study, we evaluated potential risks and benefits of thiotepa-based preparative regimens compared with BEAM (carmustine, etoposide, cytarabine, melphalan) in auto-SCT for diffuse large B-cell lymphoma (DLBCL, excluding PCNSL), follicular lymphoma (FL) or Hodgkin lymphoma (HL). A total of 14 544 patients (589 thiotepa and 13 955 BEAM) met the eligibility criteria, and 535 thiotepa- and 1031 BEAM-treated patients were matched in a 1:2 ratio for final comparison. No significant differences between thiotepa and BEAM groups for any survival end point were identified in the whole sample or disease entity subsets. For a more detailed analysis, 47 TEAM (thiotepa, etoposide, cytarabine, melphalan)-treated patients were compared with 75 matched BEAM patients with additional collection of toxicity data. Again, there were no significant differences between the two groups for any survival end point. In addition, the frequency of common infectious and non-infectious complications including secondary malignancies was comparable between TEAM and BEAM. These results indicate that thiotepa-based high-dose therapy might be a valuable alternative to BEAM in DLBCL, HL and FL. Further evaluation by prospective clinical trials is warranted.

APHP Hopital Saint louis Hemato Oncology Paris Diderot University Sorbonne Paris Cité Paris France

Cardarelli Hospital Napoli Italy

Department of Hemato Oncology Faculty Hospital Olomouc and Faculty of Medicine and Dentistry Palacky University Olomouc Czech Republic

Department of Hematology and Oncology Helios Hospital Erfurt Erfurt Germany

Department of Hematology Azienda Ospedali Riuniti Villa Sofia Cervello Palermo Italy

Department of Hematology Freiburg University Medical Center Freiburg Germany

Department of Hematology Pitié Salpêtrière Hospital Paris France

Department of Medicine 5 University Hospital Heidelberg Heidelberg Germany

Hematologie Hospices Civils de Lyon and Université Claude Bernard Lyon 1 Pierre Bénite France

Hematology Department Centre Leon Berard Lyon France

Hematology Department Paoli Calmettes Institute Marseille Aix Marseille University Marseille France

Hematology Unit Arcispedale S Maria Nuova IRCCS Reggio Emilia Italy

Hematology Unit Ospedale Civile Piacenza Italy

Hematology Unit S Maria delle Croci Hospital Ravenna Italy

Institut Català d'Oncologia Hospital Duran i Reynals Barcelona Spain

LIRIC U995 Hematology Department and Hematopoietic Stem Cell Transplantation Unit University Hospital of Lille Lille France

Lymphoma Working Party European Society for Blood and Marrow Transplantation Paris France

Service d'Hématologie Clinique Hôpital Robert Debré Centre Hospitalier Universitaire de Reims Reims France

University Hospital Düsseldorf Department of Hematology Oncology and Clinical Immunology Heinrich Heine University Düsseldorf Germany

University of Napoli Napoli Italy

University of Perugia Perugia Italy

Zobrazit více v PubMed

Ann Oncol. 2007 Jan;18(1):149-57 PubMed

J Clin Oncol. 2010 Sep 20;28(27):4184-90 PubMed

Bone Marrow Transplant. 2004 Jan;33(1):19-24 PubMed

J Neurooncol. 2012 May;107(3):659-63 PubMed

Leuk Lymphoma. 2005 Oct;46(10):1441-8 PubMed

Bone Marrow Transplant. 2009 Jul;44(2):89-96 PubMed

N Engl J Med. 1995 Dec 7;333(23):1540-5 PubMed

Bone Marrow Transplant. 2010 Feb;45(2):219-34 PubMed

Blood. 2011 Sep 22;118(12):3419-25 PubMed

Cancer Res. 1989 Feb 1;49(3):736-41 PubMed

Leuk Lymphoma. 1995 May;17 (5-6):427-33 PubMed

Bone Marrow Transplant. 2000 Feb;25(3):309-13 PubMed

J Clin Oncol. 2008 May 20;26(15):2512-8 PubMed

Bone Marrow Transplant. 2010 Apr;45(4):801-2 PubMed

Bone Marrow Transplant. 2007 Nov;40(10):919-24 PubMed

Biol Blood Marrow Transplant. 1997 Nov;3(5):261-6 PubMed

Bone Marrow Transplant. 2012 Feb;47(2):311-2 PubMed

J Neurooncol. 2014 May;118(1):155-62 PubMed

Lancet. 2002 Jun 15;359(9323):2065-71 PubMed

Biol Blood Marrow Transplant. 2015 Jun;21(6):1046-53 PubMed

Bone Marrow Transplant. 2003 Aug;32(3):279-85 PubMed

J Clin Oncol. 2006 Aug 20;24(24):3865-70 PubMed

Leuk Lymphoma. 2008 Oct;49(10):1899-906 PubMed

Blood. 2014 Nov 6;124(19):3029-31 PubMed

Hematology. 2012 Jan;17(1):23-7 PubMed

Leuk Lymphoma. 2004 Nov;45(11):2253-9 PubMed

Haematologica. 2013 May;98(5):765-70 PubMed

Haematologica. 2013 Mar;98(3):364-70 PubMed

Bone Marrow Transplant. 2009 Jan;43(1):37-42 PubMed

Bone Marrow Transplant. 2004 Nov;34(9):781-6 PubMed

Biol Blood Marrow Transplant. 2006 Jul;12(7):770-7 PubMed